ATE413394T1 - Guanidin-derivate von chinazoin zur behandlung von autoimmunkrankheiten - Google Patents
Guanidin-derivate von chinazoin zur behandlung von autoimmunkrankheitenInfo
- Publication number
- ATE413394T1 ATE413394T1 AT01940757T AT01940757T ATE413394T1 AT E413394 T1 ATE413394 T1 AT E413394T1 AT 01940757 T AT01940757 T AT 01940757T AT 01940757 T AT01940757 T AT 01940757T AT E413394 T1 ATE413394 T1 AT E413394T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- alkyl
- aryl
- group
- treatment
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 title 1
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 abstract 2
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0015376A GB0015376D0 (en) | 2000-06-24 | 2000-06-24 | Quinazoline derivatives |
| GB0030989A GB0030989D0 (en) | 2000-12-19 | 2000-12-19 | Quinazoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE413394T1 true ATE413394T1 (de) | 2008-11-15 |
Family
ID=26244531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01940757T ATE413394T1 (de) | 2000-06-24 | 2001-06-19 | Guanidin-derivate von chinazoin zur behandlung von autoimmunkrankheiten |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7001904B1 (de) |
| EP (1) | EP1296973B1 (de) |
| AT (1) | ATE413394T1 (de) |
| AU (1) | AU7425801A (de) |
| DE (1) | DE60136459D1 (de) |
| WO (1) | WO2002000644A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0012157A (pt) | 1999-07-07 | 2002-04-02 | Astrazeneca Uk Ltd | Derivado de quinazolina, derivado de pirimidina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, método para a prevenção ou tratamento de doenças ou condições médicas pela célula t um em animal de sangue quente em necessidade de tal tratamento |
| AU2002217999A1 (en) | 2000-11-01 | 2002-05-15 | Cor Therapeutics, Inc. | Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides |
| DE10345875A1 (de) * | 2003-09-30 | 2005-04-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Vewendung und Verfahren zu ihrer Herstellung |
| AU2007221049A1 (en) * | 2006-02-28 | 2007-09-07 | Amgen Inc. | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors |
| US20070231298A1 (en) * | 2006-03-31 | 2007-10-04 | Cell Genesys, Inc. | Cytokine-expressing cancer immunotherapy combinations |
| WO2008020302A2 (en) * | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| WO2012051182A2 (en) | 2010-10-11 | 2012-04-19 | University Of Houston System | Fabrication of single-crystalline graphene arrays |
| WO2012151141A2 (en) * | 2011-05-03 | 2012-11-08 | University Of Houston System | A facile preparation of 4-substituted quinazolines and related heterocycles |
| US9388126B2 (en) | 2012-07-19 | 2016-07-12 | Drexel University | Sigma receptor ligands and methods of modulating cellular protein homeostasis using same |
| CN103288760B (zh) * | 2013-05-16 | 2015-02-18 | 苏州明锐医药科技有限公司 | 卡奈替尼的制备方法 |
| WO2019089902A1 (en) | 2017-11-01 | 2019-05-09 | Drexel University | Compounds, compositions, and methods for treating diseases |
| CN116462669B (zh) * | 2023-06-20 | 2023-09-22 | 中国药科大学 | 一种sos1和egfr双靶点化合物及其制法和应用 |
| CN121816354A (zh) * | 2023-06-26 | 2026-04-07 | 阿索斯治疗公司 | 用于治疗自身免疫性疾病的小分子 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5773459A (en) | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| NZ510991A (en) | 1997-03-05 | 2002-11-26 | Sugen Inc | Use of formulations for hydrophobic pharmaceutical agents in treatment or prevention of cell proliferative disorders |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| AU750322B2 (en) | 1997-05-09 | 2002-07-18 | Trustees Of The University Of Pennsylvania, The | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| AU7585498A (en) | 1997-05-23 | 1998-12-11 | Bayer Corporation | Inhibition of p38 kinase activity by aryl ureas |
| AR016817A1 (es) | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
| BR0012157A (pt) * | 1999-07-07 | 2002-04-02 | Astrazeneca Uk Ltd | Derivado de quinazolina, derivado de pirimidina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, método para a prevenção ou tratamento de doenças ou condições médicas pela célula t um em animal de sangue quente em necessidade de tal tratamento |
-
2001
- 2001-06-19 DE DE60136459T patent/DE60136459D1/de not_active Expired - Fee Related
- 2001-06-19 WO PCT/GB2001/002698 patent/WO2002000644A1/en not_active Ceased
- 2001-06-19 AU AU74258/01A patent/AU7425801A/en not_active Abandoned
- 2001-06-19 EP EP01940757A patent/EP1296973B1/de not_active Expired - Lifetime
- 2001-06-19 US US10/311,587 patent/US7001904B1/en not_active Expired - Fee Related
- 2001-06-19 AT AT01940757T patent/ATE413394T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US7001904B1 (en) | 2006-02-21 |
| EP1296973A1 (de) | 2003-04-02 |
| EP1296973B1 (de) | 2008-11-05 |
| DE60136459D1 (de) | 2008-12-18 |
| WO2002000644A1 (en) | 2002-01-03 |
| AU7425801A (en) | 2002-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20020042D0 (no) | Kinazolinderivater | |
| DE69921986D1 (de) | Benzamid-derivate zur behandlung cytokin-vermittelter krankheiten | |
| DE60136459D1 (de) | Guanidin-derivate von chinazoin zur behandlung von autoimmunkrankheiten | |
| IL141979A0 (en) | Benzamide derivatives and their use as cytokine inhibitors | |
| AU2001235804A1 (en) | Therapy | |
| MY128501A (en) | Amide derivatives | |
| ATE303357T1 (de) | Amid-derivate | |
| RU94027563A (ru) | Соединения-ингибиторы вич протеазы, их использование для лечения спида, форикомпозиция | |
| MY140729A (en) | Amide derivatives | |
| NO20021728L (no) | Pyrimidin derivater | |
| TW200701981A (en) | Heterocyclic antiviral compounds | |
| MXPA04003304A (es) | Composiciones liquidas de administracion oral que contienen guaifenesina y un copolimero en bloque de polioxialquileno. | |
| CA2455181A1 (en) | Benzimidazo[4,5-f]isoquinolinone derivatives | |
| TR199701647A2 (xx) | �kame edilmi� purin t�revleri,bunlar�n imalat usul� | |
| NZ330944A (en) | Peptide derivatives | |
| SE9902551D0 (sv) | Novel compounds | |
| MY134019A (en) | Aryl oxime-piperazines useful as ccr5 antagonists | |
| DE60217904D1 (de) | Verwendung von quinazolinen zur behandlung von t-zell vermittelten krankheiten | |
| PH12022550345A1 (en) | Drug delivery system for the delivery of antiviral agents | |
| KR870005641A (ko) | 고혈압 치료용 조성물 | |
| GB9621836D0 (en) | Peptide compounds | |
| HUP0203161A2 (hu) | Benzamidinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| ATE295838T1 (de) | Benzimidazolderivate zur behandlung von mit mikroglia-aktivierung assoziierten erkrankungen wie inflammatorische, allergische, infektiöse oder autoimmune erkrankungen | |
| MY138502A (en) | Novel alkansulfonamides as endothelin antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |